Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
Avidity Biosciences +0.57%
Avidity Biosciences RNA | 47.51 | +0.57% |
Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:
RNA) with a Buy and maintains $60 price target.